Practice nursing care for Clients with Cancer II: Nursing Interventions
Related to Side Effects of Treatment
GYNECOLOGIC CANCERS
Molecular Biology of Gynecologic
Cancers
ENDOMETRIAL
CANCER
Although this most common gynecologic cancer carries
the best prognosis, it is important to differentiate between the classic
endometrioid tumors that tend to be estrogen dependent and well differentiated,
from other less common high-risk uterine malignancies, such as uterine
papillary serous carcinomas (UPSCs), clear cell carcinomas, mixed mullerian
tumors (MMTs), or sarcomas, which appear to have a different biology.
MICROSATELLITE
INSTABILITY
The replication error (RER+) phenotype is
characteristic of cancers arising in HNPCC kindreds (a familial cancer syndrome
with a high incidence of colon, endometrial, gastric, and a lower incidence of
ovarian and pancreatic cancers), and is also found in approximately 20% of
sporadic endometrial cancers. The RER+ phenotype per se does not appear to
correlate with clinicopathologic features of the tumors or clinical outcome;
thus the hereditary form of endometrial cancer alone does not appear to portend
a worse prognosis than the sporadic form. Mutation of the transforming growth
factor (TGF) beta receptor type II gene is common in RER+ colon and gastric
cancers, but uncommon in RER+ endometrial cancers even those arising in HNPCC
kindreds, suggesting that the genesis of RER+ tumors even within the same
familial cancer syndrome is not the same. Among sporadic endometrial cancers,
when present, the microsatellite instability is confined to the malignant
cells, and is not seen in the adjacent normal epithelium. Although inactivation
of both alleles of either hMSH2 or MLH1 (DNA mismatch repair genes) appears to
underlie microsatellite instability in tumors of HNPCC kindreds, similar to the
findings in sporadic colon cancers, sporadic endometrial cancers were not
associated with mutations of any of the four known human mismatch repair genes.
In contrast, 25% of uterine sarcomas, an entity not recognized to be part of a
familial cancer syndrome, exhibits microsatellite instability that may be
related to a mutation in the hMSH2 gene. Again, clinical outcome was not
correlated with RER+ status in those tumors; thus this finding does not
underlie the more aggressive biology of the sarcomas.
LOSS OF HETEROZYGOSITY AND TUMOR SUPPRESSOR
GENES
Unlike most other cancers studied so far,
endometrial cancer is not characterized by a small number of loci that are
involved by loss of heterozygosity. In endometrial cancers, most chromosomes
contain regions of sustained allelic loss. Chromosome 17p is frequently
involved, which contains the p53 gene known to confer a poor prognosis in
endometrial cancers when mutated or deleted, and which plays an important role
in the transition to carcinoma from atypical hyperplasia. Other frequently
involved regions include 10q, 3p, and 18q, with no significant differences
found in the chromosomal regions involved in endometrial from cervical cancers.
Chromosome 18q contains the DCC gene, a putative tumor suppressor gene
frequently mutated in colon cancers. While no mutations were found in the exons
of the DCC gene in endometrial cancers, chromosome 18 was found to be capable
of suppressing tumorigenicity of endometrial cancer cells in nude mice by the
procedure of microcell fusion, with DCC expression elevated in most of the
suppressed hybrids. These data strongly suggest that some gene on chromosome
18, is a tumor suppressor gene in endometrial cancers.
ONCOGENES
Kirsten (Ki)-ras activating point mutations in
codons 12 and 13 have been implicated in the development of atypical
endometrial hyperplasias and endometrioid carcinomas in Japanese women, as well
as in colon cancers. Recent studies of endometrial cancers arising in US women,
however, show the prevalence of such mutations to be significantly lower (11%
versus 31%) than in
Overexpression of HER-2/neu has been
associated with advanced stage, deep myometrial invasion, and poor survival in
endometrial cancers in several studies. Gene amplification did not underlie all
cases of HER-2/neu overexpression, although both gene amplification and
overexpression were each associated with poor outcomes. When multivariate
analysis was used to determine if HER-2/neu was an independent prognostic
factor in endometrial cancers taking into account other molecular features such
as DNA ploidy, epidermal growth factor receptor, or p53 status, HER-2/neu
status failed to achieve significance. Both c-myc gene amplification and c-fms
overexpression have also been associated with advanced stage and high grade
endometrial cancers.
HORMONE-RELATED
MOLECULAR ABNORMALITIES
This is a logical direction for endometrial
cancer research, because estrogen acts as a tumor promoter for the classic endometrioid
cancers. Aromatase cytochrome p450 is part of the complex responsible for
conversion of C19 steroids to estrogen; its increased expression in endometrial
cancers, but not in normal endometria, suggests a role in promotion of
neoplastic proliferation.
The findings of both gonadotropin-releasing
hormone (GnRH) (the ligand) and its receptor, as well as the luteinizing
hormone (LH) receptor in endometrial cancers may serve as a rationale for the
therapeutic use of GnRH analogues in the treatment of endometrial cancer
(although this approach has not been shown to be clinically relevant to date).
GnRH analogues may act directly on GnRH-sensitive cancers, as well as
indirectly by decreasing systemic LH levels. A clue to the signal transduction
pathway of GnRH comes from data in ovarian cancers, where GnRH has an
antimitogenic effect by stimulating protein tyrosine phosphatase activity.
Tamoxifen has been associated with an
increased risk of development of endometrial cancers, with a possible preferential
risk for the high grade nonendometrioid subtypes, such as UPSC or MMTs,
although this is controversial. Molecular abnormalities associated with UPSC
include overexpression of p53 and c-myc gene amplification; p53 overexpression
correlated with a poor prognosis. Two functional different isoforms of
progesterone receptor have been described, which may account for some of the
tissue-specific differences in the effects of progestins and antiprogestins on
the breast as compared with the endometrium.
MOLECULES
INVOLVED IN ADHESION AND INVASION
Integrin (cell adhesion molecules) expression
inversely correlates with grade in endometrial cancers, with the loss of the
alpha(2)beta(1)-integrin associated with lymph node metastases. Variant forms
of CD44 (a molecule important for cell adhesion and migration) were less
frequently expressed in endometrial cancers than in normal endometria, and
absence of CD44 was significantly associated with an increased propensity for
lymph-vascular space invasion. These data suggest that CD44 may play an
important role in the function of the normal endometria, where it is strongly
expressed near the basement membrane, and its loss may be related to invasion
and metastasis.
OVARIAN CANCER
Most of the recent breakthroughs in understanding
the molecular basis for this disease has been in the area of hereditary
epithelial ovarian cancer syndromes, which affect up to 5% of ovarian cancer
cases. Much work is still needed to understand the biology underlying sporadic
ovarian cancers, which invariably present as advanced stage disease and have a
poor long-term outcome.
CERVICAL AND
VULVAR CANCER
The study of the role of viruses in the
carcinogenesis of lower genital tract malignancies (thought to be a field
effect) has focused on cervical cancer, the third most common gynecologic
cancer in the
HUMAN
PAPILLOMAVIRUS. That HPV is a critical factor for cervical
carcinogenesis, and that the HPV E6 and E7 genes are oncogenic are clearly
established. Infection of human keratinocytes by the oncogenic HPV subtypes
leads to abnormalities in differentiation and growth; however, only after
long-term culture of immortalized cells does an occasional clone become
tumorigenic in nude mice, suggesting that HPV infection alone is not sufficient
for cervical carcinogenesis. This is supported by data from transgenic mice
studies, where E6/E7 genes can give rise to hyperplastic and neoplastic lesions
of epithelial cell types after a latent period, however, epidermoid cervical
cancers have not been noted. Cervical cancers of mesenchymal origin were noted
to arise after a long latent period in some of the female progeny of transgenic
mice into whom HPV-18 LCR/E6/E7 was introduced. While the majority of invasive
cancers contain integrated forms of HPV, usually at fragile sites that result
in cis activation of protooncogenes such as c-myc, and the large majority of
dysplasias contain episomal forms of HPV, this is not always the case. In
invasive cancers, HPV-18 is always found to be integrated in the host genome,
while HPV-16 can be found in an episomal location one third of the time. When
DNA integration occurs, it does so by preferentially disrupting the E2 open
reading frame, thus, the negative effect of the E2 protein on E6/E7 transcriptional
activity; or in such a way that transcriptional initiation from host sequences
gives rise to overexpression of E6/E7. High level transcription of E6/E7 is
seen in CIN 3 and invasive cancers when compared to CIN 1 and 2. Such
overexpression has been shown in vitro to lead to radioresistance of cervical
cancer cells. Among both low grade and high grade dysplasias, the presence of
oncogenic HPV subtypes has been reported to be closely associated with
monoclonality.
MOLECULAR COFACTORS IMPORTANT TO CERVICAL
CARCINOGENESIS
Because HPV infection is not sufficient for
cervical carcinogenesis, attention has focused on molecular cofactors important
to this process, such as coinfection by HSV-2, and the presence of activated Ha-ras;
the latter results in rearrangements and amplifications of the HPV-16 sequence.
Many positive and negative transcriptional regulators of E6/E7 transcription
have been identified. The presence of the glucocorticoid response element 5' of
the HPV genome probably underlies the clinical progression of HPV infection
seen in pregnancy. Although retinoic acid represses HPV transcription in normal
and malignant cells, its induction of retinoic acid receptor beta is restricted
to normal cells. Both the retinoic acid receptor beta gene and a locus on
chromosome 11q23 may have tumor suppressive properties in epidermoid cancer.
Loss of heterozygosity studies demonstrate allelic loss of many chromosomes
including 11q, but most frequently involving 3p, 6p, and 18q.
The immune response is likely to be key in
determining malignant transformation of HPV-infected cervical epithelium. The
consequences of human immunodeficiency virus infection include a dramatic
increase in the risk for cervical dysplasia and invasive cancer, the degree of
which correlates with the level of immunosuppression. Loss of expression of HLA
class I alleles along with interference with the transporter associated with
antigen presentation in cervical cancers is common; such changes may influence
specific immunogenic presentation by tumors. In addition, the finding of
certain HLA class II haplotypes in the cancer (when compared to cervical DNA
from controls), which may influence the immune response to specific HPV-encoded
epitopes, may contribute to the development of cervical neoplasia. Similar
findings were seen when HLA class II haplotypes in CIN were compared to
controls; the HLA DQB1 haplotype was significantly more associated with CIN.
In general, more than 90% of squamous cell
cervical cancers contain HPV DNA, and rarely p53 mutations are seen. p53
mutations appear to be more common in HPV-negative cancers, although
HPV-negative cancers that do not contain p53 mutations exist. The latter do not
contain MDM2 gene (capable of binding to p53) amplifications either. Among
HPV-negative tumors, c-myc overexpression has been associated with an increased
risk of metastasis in early stage disease. Among HPV-positive cancers, nuclear
c-myb expression was correlated with presence of HPV; c-myb can transactivate
the HPV-16 promoter, as it can HIV-1 and c-myc. In most studies, HPV status was
not a strong independent prognosticator of outcome in cervical cancer patients;
however, there appears to exist a trend for HPV-negative tumors to do worse.
NON-HPV-RELATED MOLECULAR ABNORMALITIES IN CERVICAL
CANCERS
Expression of other cell cycle genes such as
bcl-1 and bcl-2 has been studied in cervical cancer. Bcl-1 (cyclin D1) is
capable of binding to the Rb protein, and is overexpressed and amplified in the
majority of cervical and vulvar cancer cell lines, and its level of expression
is elevated by activated CSF-1 receptor. Bcl-2 overexpression, which protects
against apoptosis and differentiation, was not found to relate to HPV status,
but was more likely to be seen in CIN 3 rather than low grade dysplasias; thus,
its expression may be early event important to malignant transformation. In
vitro, increased bcl-2 expression is noted in cervical cancer cell lines that
contain an inactive p53.
Proteinases capable of degrading extracellular
matrix may underlie the propensity of cervical cancer to invade adjacent
tissues. Both the expression (as measured by reverse transcriptase in situ PCR
and activity of metalloproteinases have been described in cervical cancers, with
more activity seen than in ovarian or endometrial cancers; the opposite finding
is seen for expression of TIMP-
CARCINOMA OF
THE CERVIX
EPIDEMIOLOGY
The American Cancer Society estimates that
there will be 15,800 new cases of invasive cervical cancer and 65,000 cases of
carcinoma in situ diagnosed in the
Cervical cancer continues to be the leading
cause of cancer deaths for women of many economically underdeveloped countries.
Incidence and death rates are particularly high in Latin America, Africa,
Squamous cell carcinoma of the cervix and its
intraepithelial precursor follow a pattern typical of sexually transmitted
disease. The risk of cervical cancer is increased in prostitutes and in women
who have first coitus at a young age, multiple sexual partners, sexually
transmitted diseases, or who bear children at a young age. Promiscuous sexual
behavior in male partners may also be an important risk factor. Other factors
associated with cervical cancer include cigarette smoking, immunodeficiency,
vitamin A and C deficiency, and possibly oral contraceptive use. In the
Recent studies suggest that the number of
cervical adenocarcinomas affecting young women in their 20s and 30s may have
increased. Although, on the basis of epidemiologic studies, some investigators
have suggested an association between adenocarcinoma and prolonged oral
contraceptive use, [ref: 9] others have questioned the validity of these
conclusions because of the many potential confounding risk factors.
Molecular
studies have demonstrated a strong relationship between human papillomavirus
(HPV), cervical intraepithelial neoplasia (CIN), and invasive carcinomas of the
cervix. HPV DNA has been identified in more than 60% of cervical
cancers; HPV DNA transcripts and protein products also have been identified in
invasive cervical carcinomas. In high-grade CIN and invasive carcinoma, the
papillomavirus DNA is typically integrated into the human genome rather than
remaining in an intact viral capsid. Many of the more than 70 HPV identified
subtypes have been isolated, sequenced, and cloned. Types 6 and 11 usually
cause benign warts (condyloma acuminata), but are occasionally associated with
invasive lesions. Types 16, 18, 31, and 33 are commonly associated with
high-grade CIN and invasive cervical cancer. HPV-18 has been associated with
poorly differentiated carcinomas, an increased incidence of lymph node
involvement, and a high rate of disease recurrence, whereas HPV-16 has been
associated with large cell keratinizing tumors and a lower recurrence rate. It
has been theorized that HPV-mediated carcinogenesis results from the binding of
E6 and E7 proteins (produced by HPV-16 and HPV-18) to Rb and p53 tumor
suppressor proteins, interfering with the normal regulation of cell
proliferation.
Although most recent investigators have
concluded that HPV is probably an important factor in cervical carcinogenesis,
its role and that of other viral agents continues to be controversial. Some
investigators have argued that other viral agents, including herpes simplex
virus type II and Epstein-Barr virus, may also be important.
Human immunodeficiency virus seropositivity
has been associated with a high incidence (up to 40%) of CIN and invasive
cancer. This is at least partly due to an overlap in risk factors for the two
diseases, although changes in cell-mediated immunity may also play a role in
the development of cervical cancer. Some investigators have suggested that
cervical cancer is a more aggressive disease in these immunosuppressed
patients. For these reasons, frequent surveillance with Pap smears, pelvic examination, and colposcopy (when indicated) should
be part of the routine care of these patients. In 1993, the Center for
Disease Control added cervical cancer to the list of AIDS-defining neoplasms.
NATURAL
HISTORY AND PATTERN OF SPREAD
The junction between the primarily columnar
epithelium of the endocervix and squamous epithelium of the ectocervix is a
site of continuous metaplastic change; this change is most active in utero, at
puberty, and during first pregnancy, and declines after menopause.
Viral-induced atypical squamous metaplasia
developing in this region can progress to higher-grade squamous intraepithelial
lesions. The greatest risk of neoplastic transformation coincides with periods
of greatest metaplastic activity, and most carcinomas arise from this zone of
metaplastic transformation in the squamocolumnar junction.
The mean age of women with CIN is 15.6 years
younger than that of women with invasive cancer, suggesting a slow progression
of CIN to invasive carcinoma. In a 13-year observational study of women with
CIN 3, Miller found that disease progressed in only 14%, whereas it persisted
in 61% and disappeared in the remainder. Syrjanen and colleagues reported
spontaneous regression in 38% of high-grade HPV-associated squamous
intraepithelial lesions. However, in a large prospective study, Richart and Barron reported mean times to
development of carcinoma in situ of 58, 38, and 12 months for patients with
mild, moderate, or severe dysplasia, respectively, and predicted that 66% of
all dysplasias would progress to carcinoma in situ within 10 years. Once
tumor has broken through the basement membrane, it may penetrate the cervical
stroma directly or via vascular channels. Invasive tumors may develop as
exophytic growths protruding from the cervix into the vagina or as endocervical
lesions that can cause massive expansion of the cervix despite a relatively
normal appearing cervical portio. From the cervix, tumor may extend superiorly
to the lower uterine segment, inferiorly to the vagina, or into the
paracervical spaces via the broad or uterosacral ligaments. Tumor may become fixed
to the pelvic wall by direct extension or by coalescence of central tumor with
regional adenopathy. Tumor may also extend anteriorly to involve the bladder or
posteriorly to the rectum, although rectal mucosal involvement is a rare
finding at initial presentation. The cervix
has a rich supply of lymphatics organized in three anastomosing plexuses that
drain the mucosal, muscularis, and serosal layers. The lymphatics of the cervix
also anastomose extensively with those of the lower uterine segment, possibly
explaining the frequency of uterine extension from endocervical primary tumors.
The most important lymphatic collecting trunks exit laterally from the uterine
isthmus in three groups. Upper branches originating in the anterior and lateral
cervix follow the uterine artery, are sometimes interrupted by a node as they
cross the ureter, and terminate in the uppermost hypogastric nodes. Middle
branches drain to deeper hypogastric (obturator) nodes, and the lowest branches
follow a posterior course to the inferior and superior gluteal, common iliac,
presacral, and subaortic nodes. Additional posterior lymphatic channels
arising from the posterior cervical wall may drain to superior rectal nodes or
may continue upward in the retrorectal space to the subaortic nodes overlying
the sacral promontory. Anterior collecting trunks pass between the cervix and
bladder with the superior vesical artery to terminate in the internal iliac
nodes. Summarizes the reported incidences of pelvic and paraaortic node
involvement for patients who underwent lymphadenectomy as part of primary
surgical treatment or before radiation therapy for cervical carcinomas. The
incidences reported for radical hysterectomy series vary widely, probably
reflecting surgeons' different criteria for selecting patients for radical
surgery rather than for primary radiation treatment. Many series exclude
patients with extrapelvic disease. Variations in the completeness of
lymphadenectomies and histologic processing may also lead to underestimates of
the true incidence of regional spread from carcinomas of the cervix. Cervical
cancer usually follows a relatively orderly pattern of metastatic progression
initially to primary echelon nodes in the pelvis, then to paraaortic nodes and
distant sites. Even patients with locoregionally advanced disease rarely have
detectable hematogenous metastases at initial diagnosis of their cervical
cancer. The most frequent sites of distant
recurrence are lung, extrapelvic nodes, liver, and bone. Although the
lumbar spine is said to be a relatively frequent site of skeletal metastases,
more recent studies using abdominal imaging demonstrate that most patients with
isolated lumbar spine involvement actually have direct extension of disease
from paraaortic nodes.
PATHOLOGY
Cervical Intraepithelial Neoplasia
Several
systems have been developed to classify cervical cytology. Although criteria
for the diagnosis of CIN vary somewhat between pathologists, the important
characteristics of this lesion are cellular immaturity, cellular disorganization,
nuclear abnormalities, and increased mitotic activity. The degree of neoplasia
is determined from the extent of the mitotic activity, immature cell
proliferation, and nuclear atypia. If mitoses and immature cells are present
only in the lower one third of the epithelium, the lesion usually is designated
CIN 1. Involvement of the middle or upper third is diagnosed as CIN 2 or CIN 3,
respectively.
The term cervical intraepithelial neoplasia, as
proposed by Richart, refers only to a lesion that may progress to invasive
carcinoma. Although CIN 1-2 is sometimes referred to as mild to moderate
dysplasia, CIN is now preferred over the term dysplasia. Because the word
dysplasia means abnormal maturation, proliferating metaplasia without mitotic
activity has sometimes been erroneously called dysplasia.
The
ADENOCARCINOMA
IN SITU. The diagnosis of adenocarcinoma in situ (AIS) is made when
normal endocervical gland cells are replaced by tall, irregular columnar cells
with stratified, hyperchromatic nuclei and increased mitotic activity, but the
normal branching pattern of the endocervical glands is maintained and there is
no obvious stromal invasion. About 50% of women with cervical AIS also have
squamous CIN, and AIS is often an incidental finding in patients operated on
for squamous carcinoma.
Colposcopy
Colposcope
Microinvasive Carcinoma
Because the definition of microinvasive
carcinoma is based on the maximum depth and linear extent of involvement, it
can be diagnosed only from a specimen that includes the entire neoplastic
lesion and cervical transformation zone. This requires a cervical cone biopsy.
The earliest invasion appears as a protrusion
of cells from the stromoepithelial junction; these cells are better
differentiated than the adjacent noninvasive cells and have abundant
pink-staining cytoplasm, hyperchromatic nuclei, and small to medium nucleoli.
As the tumor progresses, invasion occurs at multiple sites, and its depth and
linear extent become measurable. The depth of invasion should be measured with
a micrometer from the base of the epithelium to the deepest point of invasion.
Although lesions that have invaded less than
Although investigators occasionally label very
small adenocarcinomas as microinvasive, the term probably should not be used for
these tumors. No definable, consistent method has been found to measure the
depth of an invasive adenocarcinoma because it may have originated from the
mucosal surface or the periphery of underlying glands. For this reason,
adenocarcinomas are generally classified as either AIS or invasive
carcinoma (FIGO stage IB).
Invasive Squamous Cell Carcinoma
Between 80% and 90% of cervical carcinomas are
squamous. A number of systems have been used to grade and classify squamous
carcinomas, but none have been consistently demonstrated to predict prognosis.
One of the most commonly used systems categorizes squamous neoplasms as either
large cell keratinizing, large cell nonkeratinizing, or small cell carcinoma.
The latter should not be (but often is) confused with anaplastic small cell
carcinoma, which resembles oat cell carcinoma of the lung because it contains
small tumor cells that have scanty cytoplasm, small round to oval nuclei, small
or absent nucleoli, coarsely granular chromatin, and high mitotic activity. In
contrast, small cell squamous carcinomas have small to medium nuclei, open
chromatin, small or large nucleoli, and more abundant cytoplasm. About 30% to
50% of anaplastic small cell carcinomas display neuroendocrine features. Most
authorities believe that patients with large cell squamous carcinoma, with or
without keratinization, have a better prognosis than those with small cell
neoplasms and that small cell anaplastic carcinomas behave more aggressively
than poorly differentiated small cell squamous carcinomas.
Invasive Adenocarcinoma
Invasive adenocarcinoma may be pure or mixed
with squamous cell carcinoma (adenosquamous carcinoma). A wide variety of cell
types, growth patterns, and differentiation have been observed. About 80% of
cervical adenocarcinomas are made up predominantly of cells whose
differentiated features resemble endocervical glandular epithelium with
intracytoplasmic mucin production. The remaining tumors are populated by
endometrioid cells, clear cells, intestinal cells, or a mixture of more than
one cell type. By histologic examination alone, some of these tumors are
indistinguishable from those arising elsewhere in the endometrium or ovary.
Minimal deviation adenocarcinoma (adenoma malignum) is an extremely
well-differentiated adenocarcinoma in which the branching glandular pattern
strongly resembles normal endocervical glands. Because of this, the tumor may
not be recognized as malignant in small biopsy specimens and the correct
diagnosis may be delayed. Earlier studies reported a dismal outcome for women
with this tumor, but more recently, patients have been reported to have a
favorable prognosis if the disease is detected early.
Young and Scully have described a
villoglandular papillary subtype of adenocarcinoma that primarily affects young
women, appears to metastasize infrequently, and has a favorable prognosis.
Glucksmann and Cherry first described glassy cell carcinoma, a form of poorly
differentiated adenosquamous carcinoma with cells that have abundant
eosinophilic, granular, ground-glass cytoplasm, large round to oval nuclei, and
prominent nucleoli. Other rare variants of adenosquamous carcinoma include
adenoid basal carcinoma and adenoid cystic carcinoma. The former is a
well-differentiated tumor that histologically resembles basal cell carcinoma of
the skin and tends to have a favorable prognosis. Adenoid cystic carcinomas
consist of basaloid cells in a cribriform or cylindromatous pattern and tend to
have an aggressive behavior with frequent metastases, although the natural
history of these tumors may be long. Whether the prognoses of these rare
subtypes are different from other adenocarcinomas of similar grade is
uncertain. A variety of neoplasms may infiltrate the cervix from adjacent
sites, presenting differential diagnostic problems. In particular, it may be
difficult or impossible to determine the origin of adenocarcinomas involving
the endocervix and uterine isthmus. Although endometrioid histology suggests
endometrial origin and mucinous tumors in young patients are most often of
endocervical origin, both histologic types can arise in either site. Metastatic
tumors from the colon, breast, or other sites may involve the cervix
secondarily. Malignant mixed mullerian tumors, adenosarcomas, and
leiomyosarcomas arise occasionally in the cervix, but more often involve it
secondarily. Primary lymphomas and melanomas of the cervix are extremely rare.
CLINICAL MANIFESTATIONS
Preinvasive
disease is usually detected during routine screening from cervical cytology.
Patients with early invasive disease may also be asymptomatic. The first
symptom of invasive cervical cancer is usually abnormal vaginal bleeding, often
following coitus or vaginal douching. This may be associated with a clear or
foul-smelling vaginal discharge. Pelvic pain may result from locoregionally
invasive disease or from coexistent pelvic inflammatory disease. Flank pain may
be a symptom of hydronephrosis, often complicated by pyelonephritis. The triad
of sciatic pain, leg edema, and hydronephrosis is almost always associated with
extensive pelvic wall involvement by tumor. Patients with very advanced tumors
may have hematuria or incontinence from a vesicovaginal fistula caused by
direct extension of tumor to the bladder. External compression of the rectum by
a massive primary tumor may cause constipation, but the rectal mucosa is rarely
involved at initial diagnosis.
DIAGNOSIS,
CLINICAL EVALUATION, AND STAGING
Diagnosis.
The long preinvasive stage of cervical cancer, relatively high prevalence of
the disease in unscreened populations, and the sensitivity of cytologic
screening have made cervical carcinoma an ideal target for cancer screening. In the
Clinical Evaluation of Patients With Invasive
Carcinoma
All patients with invasive cervical cancer
should be evaluated with a detailed history and physical examination, paying
particular attention to inspection and palpation of the pelvic organs with
bimanual and rectovaginal examinations. Standard laboratory studies should
include complete blood count and renal function and liver function tests. All
patients should have a chest radiograph to rule out lung metastases and an
intravenous pyelogram to determine the kidneys' location and to rule out
ureteral obstruction by tumor. Cystoscopy and proctoscopy or barium enema
should be obtained in patients with bulky tumors. Many clinicians obtain
computed tomography (CT) or magnetic resonance imaging (MRI) scans to evaluate
regional nodes, but the accuracy of these studies is compromised by their
failure to detect small metastases and because patients with bulky necrotic
tumors often have enlarged reactive lymph nodes.
In
a large Gynecologic Oncology Group study that compared the results of radiographic
studies with subsequent histologic findings, Heller and colleagues found that
79% of the cases with paraaortic lymph node involvement were detected by
lymphangiography whereas only 34% were detected by CT. MRI can provide useful
information about the location and depth of invasion of tumors in the cervix, but
gives less accurate assessments of parametrial involvement. Clinical Staging The International Federation of Gynecology and Obstetrics
(FIGO) has defined the most widely accepted staging system for carcinomas of
the cervix. The latest (1994) update of this system is summarized in Table.
Since the earliest versions of the cervical cancer staging system, there have
been numerous changes, particularly in the definition of stage I disease. Preinvasive
disease was not placed in a separate category until 1950, and the stage IA
category for "cases with early stromal invasion" was first described
in 1962. Cases of early stromal invasion and occult invasion were redistributed
between stages IA(i), IA(ii), and IB(occult) several times until 1985, when
FIGO eliminated stage IB(occult and provided the first specific definitions of
microinvasive disease (stages IA1 and IA2). In 1994, these definitions were
changed again and, for the first time, stage IB tumors were subdivided
according to tumor diameter. Although these changes have gradually improved the
discriminatory value of the staging system, the many fluctuations in the
definitions of stage IA and IB have complicated our ability to compare the
outcomes of patients whose tumors were staged and treated during these periods.
In addition, gynecologic oncologists in the United States have for many years
stag disease using the Society of Gynecologic Oncologists' definition of a
microinvasive carcinoma, that is, tumor that "invades the stroma in one or
more places to a depth of
PROGNOSTIC
FACTORS
Although the survival and pelvic disease
control rates of cervical cancer patients are correlated with FIGO stage,
prognosis is also influenced by a number of tumor characteristics that are not
included in the staging system. Clinical tumor diameter is strongly correlated
with prognosis for patients treated with radiation or surgery. For this reason,
FIGO recently modified the stage I category to subdivide tumors according to
clinical tumor diameter (i.e.,
In a study of sera obtained before treatment
from 587 patients with cervical cancers, Duk and colleagues reported a strong
correlation between the concentration of squamous cell carcinoma antigen and
the stage and size of the tumor as well as the presence of lymph node
metastases; multivariate analysis also showed that serum squamous cell
carcinoma antigen was an independent predictor of prognosis in their study.
Other clinical and biologic features that
have been investigated for their predictive power with variable results include
patient age, platelet count, tumor vascularity, DNA ploidy or S phase, and HPV
infection. In a preliminary study of archival material from 21 patients with
histologically negative lymph node dissections, Ikenberg and colleagues
recently reported a higher rate of disease recurrence when a polymerase chain
reaction assay of the lymph nodes was strongly positive for HPV-16 DNA.
TREATMENT
A number of factors may influence the choice
of treatment, including tumor size, stage, and histology; evidence of lymph
node involvement; risk factors for
surgery or radiation; and patient preference.
However, as a rule, intraepithelial
lesions are treated with superficial ablative techniques, microinvasive
cervical cancers invading less than
Preinvasive
Disease (Stage 0)
Patients with noninvasive squamous lesions can
be treated with
superficial ablative therapy (cryosurgery or laser therapy) or
with loop excision if (1) the entire
transformation zone has been visualized
colposcopically, (2) directed biopsies are consistent with Pap smear results, (3) endocervical curettage
findings are negative, and (4) there is
no cytologic or colposcopic suspicion of occult
invasion. If patients do not meet these criteria, a conization
should be performed.
With cryotherapy, abnormal tissue is frozen
with a supercooled metal probe until an
ice ball forms that extends
Many practitioners now consider loop diathermy
excision to be the preferred treatment.
With this technique, a charged electrode is used to excise the entire transformation zone and
distal canal.
Microinvasive
Carcinoma (Stage IA)
The standard treatment for patients with stage
IA1 disease is total (type
I) or vaginal hysterectomy. Because the risk of pelvic lymph node metastases from these minimally invasive
tumors is less than 1%, pelvic lymph
node dissection is not usually recommended. Selected patients with tumors that
meet the Society of Gynecologic
Oncologists' definition of microinvasion (FIGO stage IA1 disease without lymph-vascular space invasion) and
who wish to maintain fertility may be
adequately treated with a therapeutic cervical
conization if the margins of the cone are negative. In 1991, Burghardt and
colleagues reported one recurrence (which was fatal) in 93 women followed for more than 5 years after
therapeutic conization for minimal (less
than
Diagnostic or therapeutic conization for
microinvasive disease is usually
performed with a cold knife or carbon dioxide laser on a patient under general or spinal anesthesia.
Because an accurate assessment of the
maximum depth of invasion is critical, the entire specimen must be sectioned and carefully
handled to maintain its original
orientation for microscopic assessment. Complications occur in 2% to 12% of patients, are related
to the depth of the cone, and include
hemorrhage, sepsis, infertility, stenosis, and cervical incompetence. The width and depth of the cone
should be tailored
to produce the least amount of injury while providing clear surgical margins.
For patients with 3 to
Stages IB and IIA
Early stage IB cervical carcinomas can be
treated effectively with
combined external-beam irradiation and brachytherapy or with
radical hysterectomy and bilateral
pelvic lymphadenectomy. The goal of both
treatments is to destroy malignant cells in the cervix,
paracervical tissues, and regional lymph
nodes.
Overall survival rates for patients with stage IB
cervical cancer treated with surgery or
radiation usually range between 80% and 90%,
suggesting that the two treatments are equally effective.
However, biases introduced by patient
selection, inconsistencies in the definition of
FIGO stage IB disease, and variable indications for postoperative radiotherapy or adjuvant hysterectomy
confound comparisons about the efficacy
of radiotherapy versus surgery.
In
a 1976 review of 321 patients, Morley and Seski reported similar 5-year survival rates of 91.3%
and 87.3% for patients treated with
surgery or radiotherapy, respectively. Though treatment was assigned alternately for most patients in
this series, the study was not truly
randomized; exclusion of some patients found to have unfavorable findings at surgery and deviations
from the alternating scheme could have
led to biased results. In another review of their experience, Hopkins and Morley noted
that a significant difference in
survival favoring surgical treatment disappeared when the authors excluded from the radiation group
patients who were selected for radiation
treatment only after radical hysterectomy was
aborted because of intraoperative findings of extrauterine disease. Because young women with small, clinically
node-negative tumors tend to be favored
candidates for surgery and because tumor diameter and nodal status are inconsistently described in
published series, it is difficult to
compare the results reported for patients treated with the two modalities.
Preliminary results of the first prospective
trial randomizing
patients with stage IB or IIA cervical cancer to radical surgery
or radical radiotherapy were recently
reported. In the surgical arm, findings
of parametrial involvement, positive margins,
deep stromal invasion, or positive nodes led to the use of postoperative pelvic irradiation in 62 (54%)
of 114 patients with tumors
For
patients with stage IB1 squamous carcinomas, the choice of treatment is based primarily on patient
preference, anesthetic and surgical
risks, physician preference, and an understanding of the nature and incidence of complications with
the two treatment approaches (described
in detail later). The overall rate of major
complications is similar for patients with comparable tumors
treated with surgery or radiotherapy,
although urinary tract complications
tend to be more frequent after surgical treatment, and bowel complications are more common after radiation
therapy. Surgical
treatment tends to be preferred for young women with small
tumors because it permits preservation
of ovarian function and may cause less vaginal shortening. Radiation therapy is
often selected for older, postmenopausal
women to avoid the morbidity of a major surgical procedure.
Some surgeons have also advocated the use of
radical hysterectomy as
initial treatment for patients with larger (stage IB2) tumors. However,
patients who have tumors measuring more than
RADICAL HYSTERECTOMY.
The standard surgical treatment for stages IB
and IIA cervical carcinomas is radical (type III) hysterectomy and bilateral pelvic lymph node dissection. This
procedure involves en bloc removal of
the uterus, cervix, and paracervical, parametrial, and paravaginal tissues to the pelvic sidewalls
bilaterally, taking as much of the
uterosacral ligaments as possible.
The uterine vessels are ligated at their origin,
and the proximal one third of the vagina
and paracolpos are resected. For women younger
than 40 to 45 years, the ovaries usually are not removed. If
intraoperative findings suggest a need for postoperative pelvic irradiation, the ovaries may be transposed
out of the pelvis. Intraoperative and
immediate postoperative complications of radical hysterectomy include blood loss
(average
Although most patients have transient
decreased bladder sensation after
radical hysterectomy, with appropriate management severe long-term bladder complications are infrequent.
However, chronic bladder hypotonia or
atony occur in approximately 3% to 5% of
patients, despite careful postoperative bladder drainage. Bladder atonia
probably results from damage to the bladder's
innervation and may be related to the extent of the parametrial and paravaginal dissection. Radical hysterectomy
may be complicated by stress
incontinence, but reported incidences vary
widely. Patients may also experience constipation and, rarely, chronic
obstipation after radical hysterectomy.
RADIATION
THERAPY AFTER RADICAL HYSTERECTOMY.
The
role of postoperative irradiation in
patients with cervical carcinoma has not
yet been clearly established. Most investigators have reported that postoperative irradiation decreases the risk
of pelvic recurrence in patients whose
tumors have high-risk features (lymph node metastasis, deep stromal invasion, insecure operative
margins, or parametrial involvement).
However, because the patients who
received postoperative radiotherapy in these studies were selected
for the high-risk features of their
tumors, it is difficult to determine the
impact of adjuvant irradiation on survival.
Stages
IB and IIA (Continued). In 1989, Kinney and colleagues retrospectively compared
the outcome of 60 patients who had postoperative
irradiation with 60 unirradiated
patients who were matched for stage (stage IB versus IIA), tumor size, and number and site of
positive nodes. There were fewer
isolated pelvic failures in the irradiated group, but there was no significant difference in survival.
However, even this study did not
characterize patients in terms of all the risk factors that can influence the choice of treatment. Some
authors have hypothesized that the dose of radiation that can be
given safely postoperatively may be
inadequate to control microscopic disease in a surgically
disturbed, hypovascular site. If this is
true, it would be an argument
for primary radiotherapeutic management of tumors with known
high-risk features.
The overall risk of major complications
(particularly small bowel
obstructions) is probably increased in patients who receive postoperative pelvic irradiation, but
inconsistencies in the methods of
analysis and the relatively small number of patients in most series make studies of this subject difficult to
interpret. Montz and colleagues reported a 20% risk of small bowel obstruction requiring
surgery in 20 patients treated with
postoperative irradiation compared with 3 (5%) of 60 patients treated with hysterectomy alone. Bandy and colleagues
reported that patients
who were irradiated after hysterectomy also had more long-term problems with bladder contraction
and instability than those treated with
surgery alone.
RADICAL RADIATION
THERAPY. Radiation therapy also achieves excellent survival and pelvic control rates in patients
with stage IB cervical cancers.
As with radical surgery, the goal of radiation
treatment is to sterilize disease in the cervix, paracervical tissues, and
regional lymph nodes in the pelvis.
Patients are usually treated with a combination of external-beam irradiation to
the pelvis and brachytherapy. Clinicians
balance external and intracavitary treatment
in different ways for these patients, weighting one or the other component more heavily. However,
brachytherapy is a critical element in
the curative radiation treatment of all carcinomas of the cervix. Even relatively small tumors that involve
multiple quadrants of the cervix are
usually treated with total doses of 80 to 85 Gy to point A. This dose may be reduced by 5% to 10% for
very small superficial tumors. Although
patients with small tumors may be treated with
somewhat smaller fields than patients with more advanced
locoregional disease, care must still be
taken to cover adequately the obturator,
external iliac, low common iliac, and presacral nodes. Radiation technique and potential complications are
discussed in more detail later.
IRRADIATION FOLLOWED
BY HYSTERECTOMY.
In
a 1969 report from
In 1991, Mendenhall and colleagues reported
no difference in pelvic disease control
or survival rates for patients treated
before or after the University of Florida adopted a policy (in the mid-1970s) of using combined treatment for
patients with bulky (
There is, therefore, no clear evidence that
adjuvant hysterectomy improves the
outcome of patients with a bulky stage IB or IIA tumor, though many clinicians continue to advocate
combined treatment. When combined
treatment is planned, the dose of intracavitary irradiation is usually reduced by about 25%. A type I
extrafascial hysterectomy is usually
performed removing the cervix, adjacent tissues, and a small cuff of the upper vagina in a plane outside
the pubocervical fascia. This procedure
involves minimal disturbance of the bladder and
ureters. Intrafascial hysterectomy is not used for cervical cancer because it
does not remove all cervical tissue, and radical hysterectomy is avoided after high-dose
irradiation because of an increased risk
of urinary tract complications.
The Gynecologic Oncology Group recently
completed a prospective randomized trial
of irradiation with or without extrafascial
hysterectomy in patients with stage IB tumors of
CHEMOTHERAPY
FOLLOWED BY RADICAL SURGERY. Since the late 1980s, a number of investigators have reported the
results of treating patients with bulky
stages IB and II cervical carcinomas with a combination of neoadjuvant chemotherapy followed by radical
surgery. Neoadjuvant chemotherapy has usually included cisplatin and
bleomycin plus one or two other drugs.
The results of these uncontrolled
studies cannot be easily compared with more traditional treatments because the series are small,
often have short follow-up, and the
criteria for patient selection are not always clear. Some or all of the patients in each of these series received
postoperative pelvic irradiation, but
detailed descriptions of this additional
treatment are not always given. There has been one report of a prospective
randomized trial comparing radical hysterectomy followed by postoperative radiotherapy with
chemotherapy followed by surgery and
irradiation. In this study, Sardi and colleagues observed similar outcomes with the two
treatments for patients who had tumors
smaller than 60 cm3 (measured ultrasonographically), but they reported a significantly better projected
4-year disease-free survival with
neoadjuvant chemotherapy for patients who had larger tumors. However, most patients had been followed for
less than 3 years at the time of the
report. Ultimately, the cost and morbidity of this triple-modality treatment may be justified
only if it proves to be more effective
than treatment with radiotherapy alone. However, studies comparing this approach with radical
irradiation have not yet been
reported.
Stages
IIB, III, and IVA
Radiation therapy is the primary treatment for
most patients with locoregionally
advanced cervical carcinoma. The success of treatment depends on a careful balance between external-beam
radiation therapy and brachytherapy,
optimizing the dose to tumor and normal tissues, and the overall duration of treatment.
Five-year survival rates of 65% to 75%,
35% to 50%, and 15% to 20% are reported for patients treated with radiotherapy alone for stages IIB, IIIB,
and IVA tumors, respectively. In a
French Cooperative Group
study of 1383 patients treated with radiotherapy according to
Fletcher guidelines, Horiot and
colleagues reported 5-year survival
rates of 76%, 50%, and 20.5% for patients with stages IIB, IIIB,
and IVA tumors, respectively. With
appropriate radiotherapy, even patients
with massive locoregional disease have a significant chance for cure.
External-beam irradiation is used to deliver
a homogeneous dose to the primary
cervical tumor and to potential sites of regional spread. An initial course of external irradiation may
also improve the efficacy of subsequent
intracavitary treatment by shrinking bulky endocervical tumor (bringing it within the range of the
high-dose portion of the brachytherapy
dose distribution) and by shrinking exophytic tumor that might prevent satisfactory placement of
vaginal applicators. For this reason,
patients with locally advanced disease usually begin with a course of external-beam treatment. Subsequent
brachytherapy exploits the inverse
square law to deliver a high dose to the cervix and paracervical tissues while minimizing the
dose to adjacent normal tissues. Although many clinicians delay
intracavitary treatment until pelvic
irradiation has caused some initial tumor regression, breaks
between external-beam and intracavitary
therapy should be discouraged, and every
effort should be made to complete the entire treatment in less than 7 to 8 weeks. The favorable results
documented in reports from large single
institutions have been based on policies that dictate relatively short overall treatment durations
(less than 8 weeks), and several studies in patients with locally advanced cervical cancer have suggested that longer
treatment courses are associated with
decreased pelvic control and survival rates.
EXTERNAL-BEAM
TECHNIQUE. High-energy photons (15 to 18 MV) are usually preferred for pelvic treatment because they
spare superficial tissues that are
unlikely to be involved with tumor. At these energies, the pelvis can be treated either with four
fields (anterior, posterior, and lateral
fields) or with anterior and posterior fields alone. When high-energy beams are
not available, four fields are usually
used because less penetrating 4 to 6 MV photons often deliver an unacceptably high dose to
superficial tissues when only two fields
are treated. However, lateral fields must be designed with great care because clinicians' estimates of
the location of potential sites of
disease on a lateral radiograph may be inaccurate. In particular, "standard"
anterior and posterior borders that have been
described in the past may shield regions at risk for microscopic regional disease in the presacral and
external iliac nodes and in the
presacral and cardinal ligaments; care must also be taken not to underestimate the posterior extent of central
cervical disease in patients with bulky
tumors. The caudad extent of disease can be determined by placing radiopaque seeds in
the cervix or at the lowest extent of vaginal disease. Information gained from radiologic studies
can also improve estimates of disease
extent. Lymphangiograms are helpful in tailoring blocks, particularly at the anterior border of
lateral fields. MRI and CT scans can
also help clinicians to design lateral field borders with an improved understanding of uterine position.
In fact, some
investigators have argued that these studies should be
obtained routinely for patients with
bulky disease to avoid errors in lateral
field design. However, when all these factors are considered, differences in the volume
treated with a four-field or a
high-energy two-field technique may be small. For this reason, some clinicians prefer to use the simpler
technique for patients with bulky
tumors.
Tumor response should be evaluated with
periodic pelvic examinations to
determine the best time to deliver brachytherapy treatment. Some practitioners prefer to maximize the
brachytherapy component of treatment and
begin as soon as the tumor has responded enough to permit a good placement (with very bulky
tumors this may still require 40 Gy or
more). Subsequent pelvic irradiation is delivered with a central block. A somewhat higher total
paracentral dose can be delivered with
this approach, but greater reliance is placed on the complex match between the brachytherapy dose
distribution and the border of the
central shield. Other clinicians prefer to give an initial dose of 40 to 45 Gy to the whole
pelvis, believing that the ability to
deliver a homogeneous distribution to the entire region at risk for microscopic disease and the
additional tumor shrinkage achieved
before brachytherapy outweigh other considerations. In fact, both approaches have been in use for several
decades and, when optimally used, appear
to give excellent tumor control rates with
acceptable complication rates.
THE ROLE OF
PARAAORTIC IRRADIATION. The role of extended-field irradiation in the treatment of cervix cancer
is still being defined. Numerous small
series of patients with documented paraaortic node involvement demonstrate that some
enjoy long-term survival after radiation
therapy. Patients with microscopic
involvement have a better survival than
those with gross lymphadenopathy, but even 10% to 15% of the latter appear to be curable with aggressive
management. Survival is also strongly
correlated with the bulk of central disease. A 1991 study by Cunningham and colleagues reported
a 48% 5-year survival rate in patients
who had paraaortic node involvement
discovered at exploration for radical hysterectomy (which was then aborted). This experience with patients who had
small, radiocontrollable primary disease
demonstrates that patients with
paraaortic node metastases can often be cured if their primary disease can be sterilized. This indicates that
patients may have extensive regional
spread without distant metastases and provides an argument for surgical staging in high-risk patients.
Two randomized prospective trials have
addressed the role of prophylactic
paraaortic irradiation in patients without known paraaortic node involvement. In a recently
updated study conducted by the Radiation
Therapy Oncology Group (RTOG), 367 patients with primary stage IIB or stages IB and IIA tumors more
than
Stages
IIB, III, and IVA (Continued)
A second trial from the European Organization
for Research and
Treatment of Cancer (EORTC) involved a similar randomization
between pelvic irradiation and extended
fields, but had very different
eligibility criteria. This study included patients with bulky stage IIB (involving distal
vagina or lateral parametrium) and III
disease and patients with stage I and less bulky stage IIB disease who had positive pelvic nodes on lymphangiogram
or at surgery. The 4-year disease-free
survival rates of 49.8% and 53.3% for patients
treated with pelvic or extended fields, respectively, were not significantly different. However, the rate of
paraaortic node recurrence was
significantly higher in the pelvic group, and for patients in whom local control was achieved,
the rate of distant metastases was 2.8
times greater if treatment was with pelvic
irradiation only (P <0.01).
Both studies revealed an increased rate of
enteric complications in patients
treated with extended fields. In the ROTG study, most small bowel obstructions occurred in patients who
had undergone pretreatment
transperitoneal staging. The EORTC did not mention a relationship between surgical staging and enteric
complications.
Although the morbidity of extended-field
irradiation is no longer prohibitive
with multiple field techniques, more modest radiation doses, and extraperitoneal staging, it is
still greater than that of standard
field radiotherapy. Further definition of patients most likely to benefit from prophylactic
paraaortic irradiation would improve the
therapeutic ratio of such treatment.
BRACHYTHERAPY
TECHNIQUE. Fletcher described the following three conditions for successful cervical
brachytherapy: (1) the geometry of the
radioactive sources must prevent underdosed regions on and around the cervix, (2) an adequate dose must be
delivered to the paracervical areas, and
(3) mucosal tolerance must be respected. These factors dictate the character, intensity, and timing
of brachytherapy.
Brachytherapy is usually delivered using
afterloading applicators that are placed
in the uterine cavity and vagina. A number of different intracavitary systems have been used; in the
BRACHYTHERAPY DOSE. Optimal placement of the
uterine tandem and vaginal ovoids
produces a pear-shaped distribution, delivering a high dose to the cervix and paracervical tissues
and a reduced dose to the rectum and
bladder.
Treatment dose has been specified in a number
of ways, making it very difficult to
compare experiences. Paracentral doses are most
frequently expressed at a single point, usually designated point A. This reference point has been calculated in a
number of different ways, but it is
usually placed
In 1985 the International Commission on
Radiation Units and
Measurements recommended that reference points like point A not
be used because "such points are
located in a region where the dose
gradient is high and any inaccuracy in the determination of
distance results in large uncertainties
in the absorbed doses evaluated at these
points." Instead, they recommended that doses be specified in terms of the following: (1)
total reference air Kerma -- expressed
in muGy at
A detailed
description of the characteristics of an ideal
intracavitary system and of the considerations that influence
source strength and position are beyond
the scope of this chapter. However, an effort should always be made to
deliver 85 Gy or more to point A for
patients with bulky central disease. If
the intracavitary placement has been optimized, this can usually be accomplished without exceeding a dose of 75
Gy to the bladder reference point or 70
Gy to the rectal reference point, doses that are usually associated with an acceptably low
risk of major complications. The dose to
the surface of the lateral wall of the apical vagina should not usually exceed 130 to 140 Gy.
Suboptimal placements occasionally force
compromises in the dose to tumor or normal tissues. To choose a treatment that optimizes the
therapeutic ratio in these circumstances
requires experience and a detailed understanding of factors that influence tumor control and
normal tissue complications.
A total dose (external beam and intracavitary)
of 50 to 55 Gy appears to be sufficient
to sterilize microscopic disease in the pelvic nodes in most patients. It is customary to boost
the dose to a total of 60 to 65 Gy in
lymph nodes known to contain gross disease and in heavily involved parametria.
BRACHYTHERAPY
DOSE RATE. Traditionally, cervical brachytherapy has been performed with sources that yield a dose
rate (at point A) of approximately 40 to
50 cGy/hr. These low dose rates permit repair of sublethal cellular injury, normal tissues are
preferentially spared, and the
therapeutic ratio is optimized. To reduce the 3 to 4 days of hospitalization needed to deliver an
appropriate dose of low-dose-rate
irradiation, some investigators have explored the use of intermediate-dose-rate brachytherapy (80 to
100 cGy/hr). However, in a randomized
trial, Haie-Meder and colleagues [ref: 275] reported a significant increase in complications when
the dose rate was doubled from 40 to 80
cGy/hr, indicating that the total dose must be reduced and the therapeutic ratio of treatment may be
compromised with higher dose rates.
Since
the 1970s, computer technology has made it possible to deliver brachytherapy at very high dose rates
(more than 100 cGy/min) with a high
activity *60Co or *192Ir source and remote afterloading. High-dose-rate intracavitary therapy is now
being used for radical
treatment of cervical cancer by a number of groups, including
several in
INTERSTITIAL
BRACHYTHERAPY. Several groups have advocated the use of interstitial brachytherapy to treat patients
whose anatomy or tumor distribution make
it difficult to obtain an ideal intracavitary
placement. Interstitial implants are usually placed transperineally, guided by a Lucite
template that encourages parallel placement of
hollow needles that penetrate the cervix and paracervical spaces; needles are usually loaded with *192Ir.
Advocates of the procedure describe the
relatively homogeneous dose distribution achieved with this method, the ease of inserting implants in
patients whose uteri are difficult to
probe, and the ability to place sources directly into the parametrium. Initial reports were
enthusiastic, describing these
theoretical advantages and high initial local control rates.
However, there have as yet been very few
reports of long-term survival rates in
patients treated with interstitial brachytherapy for primary cervical cancer. In 1986, Syed and colleagues
reported a projected
5-year survival rate of 53% for 26 patients with stage IIIB disease.
Recently several groups have been exploring
the use of MRI-guided needle placement,
interstitial hyperthermia, and high-dose-rate
interstitial therapy to improve local control and complication rates. However, outside of an investigational
setting, interstitial treatment of
primary cervical cancers should probably be limited to patients who cannot accommodate intrauterine brachytherapy
and to those with distal vaginal disease
that requires a boost with interstitial brachytherapy.
COMPLICATIONS
OF RADICAL RADIOTHERAPY. During radiotherapy of the pelvis, most patients have mild fatigue and
mild to moderate diarrhea that usually
is controllable with antidiarrheal medications; some patients have mild bladder irritation. When
extended fields are treated, patients
may have nausea, gastric irritation, and mild
depression of peripheral blood counts. Acute symptoms may be
increased in patients receiving
concurrent chemotherapy. Unless the ovaries have been transposed, all premenopausal patients
who receive pelvic radiotherapy experience
ovarian failure by the completion of
treatment.
Complications of intracavitary therapy
include uterine perforation, fever, and
the usual risks of anesthesia. Thromboembolic complications are rare. In a review of 327 patients who had
gynecologic brachytherapy
for a variety of indications, Dusenberry and colleagues reported four (1.2%) thromboembolic
complications. In a recent unpublished
review of 1784 patients treated with radiotherapy for Stage IB cervical cancer at M. D.
Anderson, there were 3 (0.17%) suspected
cases of pulmonary embolus, none of which were fatal. Patients with bulky disease on the pelvic
wall may have a somewhat greater risk of
thromboembolic events.
Estimates of the risk of late complications of
radical radiotherapy vary according to
the grading system, duration of follow-up, method of calculation, treatment method, and prevalence
of risk factors in the study population.
However, most reports quote an overall risk of major complications (requiring transfusion,
hospitalization, or surgical
intervention) of 5% to 15%. Perez and colleagues reported a crude risk of major
complications of 14.8% with a median follow-up of 12 years. In a report from the Patterns of
Care Study, Lanciano and
colleagues reported an actuarial risk of 8% at 3 years. In a study of 1784
patients with stage IB disease,
During the first 3 years after treatment,
rectal complications are most common and
include bleeding, stricture, ulceration, and fistula. In the study by
Small bowel obstruction is an infrequent
complication of standard radiotherapy
for patients without special risk factors. The risk is increased dramatically in patients who
have undergone transperitoneal lymph
node dissections. However, there appears to be little added risk if the operation
is performed with a retroperitoneal approach.
Other factors that can increase the risk of small bowel complications
in patients treated for cervical cancer
include pelvic inflammatory disease, thin body habitus, and the use of high doses or large volumes of
external-beam irradiation, particularly
with low-energy treatment beams and large daily fraction sizes.
Most patients treated with radical
radiotherapy have some agglutination and
telangiectasia of the apical vagina. More significant vaginal shortening can
occur, particularly in elderly,
postmenopausal women and those with extensive tumors treated with a high dose of irradiation. Vaginal function
can be optimized
with appropriate estrogen support and vaginal dilatation.
NEOADJUVANT
CHEMOTHERAPY. Studies that have explored combinations of chemotherapy and radiation therapy for
patients with locally advanced cervical
cancers have generally used one of two strategies. Studies of neoadjuvant
chemotherapy have attempted to exploit the high response rates of previously untreated tumors to
chemotherapy by administering systemic
agents before any local therapy, hopefully to reduce the volume of tumor treated with radiation. In
contrast, the primary goal of studies
that combine radiation therapy with concurrent chemotherapy is to use chemotherapeutic agents to
sensitize tumor cells to the effects of
radiotherapy.
Investigators
were encouraged to explore neoadjuvant treatment because of the high response rates reported
for a variety of cisplatin-containing
combinations evaluated in phase II studies of
previously untreated patients with cervical cancer. However, it was
not possible to determine from these
uncontrolled trials whether high
response rates to chemotherapy would lead to improved survival
rates. Five randomized trials
comparing neoadjuvant chemotherapy followed by
irradiation and irradiation alone have been reported. Chauvergne and colleagues randomized
151 patients with stages IIB or III
disease to receive radical radiotherapy alone or preceded by chemotherapy (cisplatin, methotrexate,
chlorambucil, and vincristine). Although
objective responses to chemotherapy were observed in 31 (43%) of 73 patients, there was no difference in
the survival or pelvic disease control
rates of patients in the two treatment arms. In a randomized study of 184 patients with
stages IIB to IVA squamous carcinomas,
Kumar and colleagues found no significant
difference in disease-free or overall survival between patients treated with bleomycin, cisplatin, and
ifosfamide followed by irradiation or
with irradiation alone. Tattersall and colleagues reported no difference in
survival when they compared chemotherapy
(cisplatin, bleomycin, and Velban) followed by pelvic irradiation with radiotherapy alone in 71
patients who had positive pelvic lymph
nodes discovered at radical hysterectomy. Souhami and colleagues reported a significantly
poorer survival rate (23% versus 39%; P
=0.02) for patients who received neoadjuvant
chemotherapy (cisplatin, bleomycin, vincristine, and mitomycin-C) in
a study of 107 patients with stage IIIB
cervical cancers. In another
large prospective trial reported by Tattersall and colleagues, 129
patients who received neoadjuvant chemotherapy (cisplatin and epirubicin) had a significantly poorer pelvic
disease control rate (P = 0.003) and
survival rate (P = 0.02) than 131 patients treated with radiation therapy alone, despite a high
initial response rate to chemotherapy
(63%).
In summary, despite high response rates of
locally advanced cervical cancers to
initial chemotherapy, none of the randomized studies reported to date has demonstrated an
improvement in outcome when neoadjuvant
chemotherapy was added to radical radiotherapy. In many ways, this recapitulates the
experience with treatment of locally
advanced head and neck cancers for which it has been hypothesized
that the failure to influence outcome
with neoadjuvant chemotherapy may
reflect cross-resistance of clonagens to drugs and radiation or accelerated repopulation of tumor clonogens
induced by neoadjuvant chemotherapy.
CONCURRENT CHEMORADIATION. A
number of investigators have reported
high response rates and encouraging survival rates in uncontrolled phase I/II studies of patients with locally
advanced cervical carcinomas treated
with concurrent chemotherapy and irradiation. Drugs that are most commonly
given concurrently with radiation
therapy include hydroxyurea, 5-fluorouracil, mitomycin-C, and cisplatin.
Hydroxyurea, a drug that has been demonstrated
in vitro to sensitize
cells to radiation by arresting them in a sensitive portion of
the cell cycle, was identified as an
attractive subject for clinical study in
the early 1970s. After a small randomized study suggested encouraging results, the
Gynecologic Oncology Group conducted a
larger study randomizing patients with stage IIIB or IVA disease either to receive oral
hydroxyurea (80 mg/kg, up to
A third Gynecologic Oncology Group study using
similar entry criteria
randomized patients to receive either hydroxyurea (80 mg/kg
orally twice weekly during external-beam
irradiation) or cisplatin (50 mg/m*2
intravenously on days 1 and 29) and 5-fluorouracil (1000 mg/m*2 as a continuous intravenous infusion
on days 2 through 5 and days 30 through
33 of radiation). This study closed to patient accrual in 1990, and the results should be analyzed
and reported soon. Ongoing studies that
address the value of chemosensitization in patients with locally advanced cervical cancer include (1)
a Gynecology Oncology Group study
randomizing patients to receive either hydroxyurea, weekly cisplatin, or a combination of hydroxyurea,
5-fluorouracil, and cisplatin during
external-beam irradiation and (2) a Radiation Therapy Oncology Group study comparing cisplatin plus
5-fluorouracil (administered in three
cycles during external-beam and intracavitary
irradiation) with extended field irradiation plus brachytherapy.
In summary,
concurrent treatment of locally advanced cervical cancers with chemotherapy and radiotherapy is an
approach that holds considerable
promise, although additional studies are needed to confirm the benefit of this treatment.
To confirm that concurrent chemotherapy
improves the therapeutic ratio achievable with radical radiotherapy, future studies also need to
provide careful documentation of the
late complications of treatment. The morbidity of radiotherapy with and without chemotherapy
has not yet been compared in a randomized
study, but one uncontrolled study suggests that late gastrointestinal toxicity may be increased
with concurrent administration of some
drugs.
INTRAARTERIAL
CHEMOTHERAPY. Intraarterial infusion of chemotherapeutic agents delivered neoadjuvantly, concurrent
with radiotherapy, or as salvage
treatment for recurrent disease has generated interest for some years because of the distinct arterial
supply to the central pelvis. A
number of drugs have been used in small pilot
studies, but 5-fluorouracil and cisplatin have been the most
popular in this setting. Unfortunately,
this technique is difficult and
invasive, the toxicity reported in some series has been
substantial, and the results have been
variable in several small series of
patients. However, occasional optimistic reports have maintained a
low level of interest in this approach,
particularly for concurrent
intraarterial chemotherapy and irradiation.
Stage IVB
Patients who present with disseminated disease
are almost always incurable. Management
of these patients must emphasize palliation of
symptoms with appropriate pain medications, and localized radiotherapy. Tumors may respond to
chemotherapy, but the duration of
responses is usually short.
SINGLE-AGENT
CHEMOTHERAPY. Fifty-two drugs have been studied in sufficient numbers of patients with carcinoma
of the cervix to assess their activity.
Nineteen of these have yielded response rates (partial and complete) of at least 15% and may be of
therapeutic value.
Several of the platinum compounds have been
evaluated in greater detail. Cisplatin
has been studied in a variety of doses and schedules. These studies have
demonstrated activity
of the drug at a dose of 50 mg/m*2 given intravenously at a rate
of 1 mg/min every 3 weeks. Although
there appears to be a small but statistically significant increase in
the response rate with a doubling of the
dose to 100 mg/m*2, this has not resulted in a
detectable improvement in the rates of progression-free or overall survival. More prolonged infusion of the same
dose over 24 hours yields a similar
response rate with less nausea and vomiting, although the recent development of more effective
antiemetic agents reduces the clinical
importance of this observation. The response rates of other platinum compounds (i.e., carboplatin and
iproplatin) are lower than those
observed with cisplatin, which remains the platinum compound of choice for patients with cervical carcinomas.
Ifosfamide has been studied as a single agent
in patients with recurrent cervical
cancer in at least five phase II trials. Response rates ranged between 33% and
50% in three studies
that were conducted in patients who had received no previous chemotherapy. However, the response rates were much lower in
two phase II trials that included patients who had received prior systemic chemotherapy, with
only three partial responses (8%) in 36
patients.
COMBINATION CHEMOTHERAPY.
Most reports of combination chemotherapy for carcinoma of the cervix have
described uncontrolled phase II trials of
drug combinations that have included at least some agents with
known activity. Most studies have been
small, with reported response rates
ranging from 0% to 100%. In general, data from these phase II studies provide no
firm evidence that any of the studied combinations are superior to single-agent therapy for patients
with disseminated or recurrent cervical
cancer. However, combinations based on ifosfamide and cisplatin and those
based on 5-fluorouracil and cisplatin
have attracted significant interest and deserve further discussion.
Several small phase II studies have evaluated
treatment with combinations of
ifosfamide and either cisplatin or carboplatinum in patients who had not received prior
radiotherapy. Response rates for these
combinations ranged between 50% and 63%. A number of investigators have
combined bleomycin with ifosfamide and a
platinum compound. Three studies included
patients who had not had prior radiotherapy, and reported response rates were 65% to 100%. Reports of treatment
with these drugs in previously
irradiated patients have yielded mixed, but
generally lower, response rates of between 13% and 72%.
Combinations of cisplatin and continuous
infusion 5-fluorouracil also
produce high response rates in previously untreated patients. Again,
response rates decrease significantly if patients have had previous irradiation.
The Gynecologic Oncology Group recently
completed a large prospective
randomized trial comparing cisplatin alone with cisplatin
plus ifosfamide and cisplatin plus
dibromodulcitol in patients with
advanced or recurrent cervical cancers. The addition of ifosfamide to cisplatin improved the
response rate (33% versus 19%, P =0.02)
and progression-free survival rate (4.6 versus 3.2 months, P < 0.05), but caused significantly greater
toxicity (leukopenia, peripheral
neuropathy, renal toxicity, and encephalopathy) and did not significantly improve the overall median
survival. The addition of
dibromodulcitol did not improve the response rate or survival duration.
PALLIATIVE RADIOTHERAPY. Localized
radiotherapy can provide effective pain
relief for symptomatic metastases in bone, brain, lymph nodes, or other sites. A rapid course of pelvic
radiotherapy can also provide
excellent relief of pain and bleeding for patients who present
with incurable disseminated disease.
Side Effects of Chemotherapy
- Anemia
- Appetite
Changes
- Bleeding
Problems
- Constipation
- Diarrhea
- Fatigue
(Feeling Weak and Very Tired)
- Hair
Loss
- Infection
- Memory
Changes
- Mouth
and Throat Changes
- Nausea
and Vomiting
- Nerve
Changes
- Pain
- Sexual
and Fertility Changes in Men
- Sexual
and Fertility Changes in Women
- Skin
and Nail Changes
- Swelling
(Fluid Retention)
- Urination
Changes
Pregnancy and contraception
Many chemotherapy drugs may cause birth
defects. It is important that a woman undergoing chemotherapy avoids becoming
pregnant. As most chemotherapy medications interfere with oral contraceptives
it is important to use a barrier method of contraception, such as condoms,
during the whole chemotherapy treatment period and for a year after treatment
is completed. If you are pregnant you need to tell the medical team straight
away beforehand. If you become pregnant during treatment tell the medical team
straight away. What are the side effects of chemotherapy?
Most people immediately link chemotherapy with
uncomfortable side effects. However, side-effect management has improved
considerably over the last twenty years. Many side effects that were once
inevitable can be either prevented or well controlled today.
There is no reliable way to predict how
patients may react to chemotherapy. Some experience very mild side-effect,
others will have none at all, while some people will report various symptoms.
Depending on the type of cancer and treatment,
chemotherapy may have a bigger impact on the patient's work status than
radiotherapy. Women with breast cancer who receive chemotherapy appear more
likely than those treated with radiation therapy to experience a major change
in work status, according to researchers at the Dana-Farber Cancer Institute.
Below is a list of the most commonly
reported side effects:
Nausea and vomiting
Over half of all patients receiving
chemotherapy will experience nausea and vomiting. Doctors will usually
prescribe anti-emetics for this. These need to be taken even when symptoms have
gone as they will prevent them from coming back. If the anti-emetics do not
work the patient should contact his/her doctor who may switch to another
anti-emetic.
Ginger - scientists at the
Alopecia (Hair loss)
Some chemotherapy medications cause hair loss
while others don't. If hair does start to fall out this will usually happen a
few weeks after treatment starts. On some occasions the hair will just become
thinner and more brittle (without falling out). Hair loss can occur in any part
of the body.
Although hair loss has no physical health
consequences, it may cause distress and embarrassment for some people. The
psychological impact tends to be greater among women than men. If you
experience hair loss and find it is causing distress and embarrassment, there
are several steps you can take:
Tell
your doctor, who may refer you to a counselor who can provide effective help
and support.
Many
people find that if they purchase a wig their quality of life improves
significantly.
If
there is a cancer support group in your area, go to their meetings. Meeting
people who share similar experiences to yourself may help give you a boost, as
well as providing you with some useful tips, and possibly an opportunity to
make new friends.
Cold
cap - this looks a bit like a bicycle helmet and keeps the scalp cool while the
chemotherapy dose is being administered. If the scalp can be kept cool less
chemotherapy medication reaches the scalp, thus preventing the occurrence or
reducing the severity of hair loss. Some people cannot wear a cold cap -
leukemia (blood cancer) patients need the medication to reach their scalp.
The hair loss is NOT permanent - it will grow
back soon after treatment if finished.
Fatigue
Most patients receiving chemotherapy will
experience some degree of fatigue. This may be a general feeling which exists
most of the day, or may only appear after certain activities. Doctors say
patients need to make sure they get plenty of rest and not to perform tasks
which are overtiring.
While light exercise has been shown to help,
it is important to remember to keep the activities 'light'.
If the tiredness becomes severe it is
important to tell the doctor, as this could be caused by a significant drop in
red blood cells (anemia).
Hearing impairment (deafness,
ototoxicity)
Scientists from
Children with cancer who suffer hearing loss
due to the toxic effects of chemotherapy might one day be able to get their
hearing back through pharmacological and gene therapy, said researchers from
St. Jude Children's
Neutropenia (low white blood cells) -
Susceptibility to infections
When receiving chemotherapy the immune system
will be weakened because the white blood cell count will go down. White blood
cells form part of our immune system - they fight infection. Consequently,
patients become more susceptible to infections.
Some patients will be prescribed antibiotics
which may reduce their risk of developing infections. The following precautions
will help reduce the risk of infections:
Personal
hygiene - the cleaner you are, the fewer bacteria there will
be around which can infect you. Regularly wash your hands with warm
water and soap, have a bath/shower at least once a
day, change your clothes and bathroom towels and flannels daily. Change your
bed linen regularly.
Preparing
food - make sure your food is free of food borne pathogens (organisms, such as
bacteria that can make you ill). If you handle raw meat make sure you wash your
hands before touching plates and cutlery or work surfaces. Thoroughly cook
animal sourced proteins before eating them. Wash your dishes thoroughly and
always use a clean plate and cutlery - keep the kitchen clean.
Infected
people - stay away from people who are ill. This may include those who just
have a temperature.
Skin wounds -
bacteria find it hard to get in through your skin, unless there is a cut. If
you graze or cut your skin, clean the area well with warm water, dry it, and
cover it with a sterile dressing.
Patients receiving chemotherapy who develop an
infection need immediate treatment. This may mean being hospitalized and
receiving antibiotics via an intravenous drip.
Thrombocytopenia (low blood platelet
count) - Blood clotting problems
Chemotherapy may lower the patient's blood
platelet count. A platelet is a type of blood cell that helps the blood to clot
(coagulate). Coagulation is essential, otherwise bleeding does not stop. Lower
blood platelet counts linked to chemotherapy is a risk, but less so than lower
red or white blood cell counts. If you are affected you will bruise more
easily, you will be more likely to have nosebleeds and bleeding gums, and if
you cut yourself it may be harder to stop the bleeding.
Patient's whose blood platelet counts fall too
low will need a blood transfusion.
Below are some steps you may wish to take to
reduce your risk of bleeding:
Shave
with an electric razor (or don't shave)
Avoid
hard toothbrushes
Use
kitchen utensils and gardening equipment carefully
If
you are gardening, wear gloves
Anemia
(low red blood-cell count)
As well as lowering you white blood cell
count, chemotherapy will also lower your red blood cell count. Tissues and
organs inside your body get their oxygen from the red blood cells. If your red
blood cell count goes down too many parts of your body will not get enough
oxygen and you will develop anemia.
People with anemia feel very tired. A patient
on chemotherapy who has anemia will feel extra tired - much more tired than
straightforward fatigue caused by the treatment. Dyspnea (shortness of breath)
is also another symptom of anemia, as are palpitations (when the heart beat is
irregular).
Anemia linked to chemotherapy requires
immediate treatment. A blood transfusion will bring the red blood cell count
back up immediately. Erythropoietin (EPO) is a drug that makes the body produce more red blood cells.
The following foods are rich in iron, which
helps red blood cells carry more oxygen. Dark green leafy
vegetables, beans, meat, nuts, prunes, raisins, and apricots.
Scientists from The Medical University of
Vienna, Austria found that patients with breast cancer who developed anemia
during chemotherapy had nearly three times the risk of local recurrence as
those who did not.
Mucositis
(inflammation of the mucous membrane)
Chemotherapy attacks rapidly dividing cells,
such as blood cells, bone marrow cells, and cells of the mucous membranes that
line the digestive system - this includes the mouth, esophagus, stomach,
intestines, and the rectum to the anus. Chemotherapy may damage and even
destroy some of those mucous membrane cells.
Oral
Mucositis (in the mouth) - patients more commonly experience symptoms in
their mouth.
If symptoms do appear, they will usually do so
about 7 to 10 days after treatment starts. The inside of the mouth may feel
like sunburn; some people say it feels as if the area had been scalded. Ulcers
often appear on the lining of the mouth, the tongue, and sometimes around the
lips. The severity of symptoms is closely linked to the strength of the
chemotherapy dose.
Some may find it painful when they eat, drink,
or even talk. If the ulcers bleed there is a risk of infection.
Caphosol is often prescribed for mucositis.
A clinical trial showed that out of 100 cancer
patients that were treated with DAVANAT® and chemotherapy that included 5-FU,
none developed mucositis.
As better drugs are appearing, mucositis is
becoming less common. Symptoms clear up a few weeks after treatment is
completed.
Loss of appetite
Loss of appetite is a common side effect of
chemotherapy. It is possible that the chemotherapy, or the cancer itself,
affects the body's metabolism. If the loss of appetite is just due to the
chemotherapy it will come back when the treatment is finished - although this
may sometimes take a few weeks.
The severity of appetite and consequent weight
loss depends on the type of cancer and chemotherapy treatment.
Although this is sometimes easier said than
done, it is important to keep trying to eat well and take in plenty of fluids.
Many patients find that smaller and more frequent meals are easier to get down
than the typical three meal-a-day regime. Also, drinking liquids through a
straw may result in a better fluid intake.
Patients who become seriously affected by lack
of food and liquid intake may need to be hospitalized and fed through a
nasogastric tube. The tube goes into the patient's nose and down to his/her
stomach.
Nails and skin
Chemotherapy can sometimes cause dry and sore
skin. Nails may also become flaky and brittle. The skin may become more
sensitive to sunlight. It is important to protect yourself from too much
sunlight exposure. This includes staying out of the sun during peak times of
the day, using sun blocks, and wearing clothes that provide maximum protection.
Surprisingly, scientists at
Cognitive problems
About one fifth of patients undergoing
chemotherapy report some kind of cognitive problem, including attention,
thinking and memory. This can sometimes have an impact on daily tasks. Patients
who do experience these symptoms should talk to their doctor, and social
worker.
Symptoms may include:
Shorter
attention span; concentration, focus and attention problems
Memory
problems; especially the short-term memory
Comprehension
and understand problems
Judgment
and reasoning problems
Organizational
skills may be affected
Multitasking
problems (performing/thinking about several things at the same time)
Mood
swings
Experts are unsure how much is due to the
chemotherapy, and how much is due to fatigue, stress and anxiety that comes with having cancer.
Libido (sex drive) and fertility
For a significant proportion of patients,
chemotherapy may result in a lower sex drive (less interest in sex). This is
temporary and usually returns after treatment is completed.
Depending on the type of medication
administered, chemotherapy may also damage men's sperm. Some women may become
infertile. In most cases - though not all - fertility returns after treatment
is over.
Men who wish to father children and women who
plan to become pregnant one day should discuss possible options with their
doctors before starting treatment. It is possible to freeze sperm and embryos.
Bowel movement problems (diarrhea or
constipation)
Sometimes when damaged cells in the intestinal
tract are rapidly expelled from the body there is a risk of diarrhea.
Constipation is also a possible risk for chemotherapy patients. You should talk
to your doctor if you experience any unpleasant change in your bowel movements.
Symptoms, if they do occur, will do so a few days after chemotherapy begins.
Depression
The risk of developing depression is already
higher for patients with cancer. It is normal to feel distressed, anxious, sad
and stressed - especially if you are concerned about what the future holds and
whether treatment is going to be effective.
It is important that you talk to a member of
the medical team if you feel it is all getting to be too much, or if you no
longer get pleasure out of the things that you used to like. Joining a support
group and talking to people who are going through the same as you and
understand how you feel has helped many people with cancer. Protecting the gut
from chemotherapy in cases of metastatic cancer
When cancer has spread beyond the primary
tumor to other parts of the body, i.e. when it has metastasized, treatments
tend to involve intensive chemoradiotherapy. These high doses of raditation
therapy and chemotherapy damage good tissue and often push the patient to an
early death.
Researchers from the University of Michigan School of Dentistry reported in the journal
Nature that they found a way to preserve the health of the gut in laboratory
mice that had been given very high doses of chemoradiotherapy.
Team leader, Jian-Guo Geng, said "All
tumors from different tissues and organs can be killed by high doses of
chemotherapy and radiation, but the current challenge for treating the
later-staged metastasized cancer is that you actually kill the patient before
you kill the tumor."
Healthy
digestive tract improves survival - the scientists found that if the gut of
mice with metastatic cancer stayed healthy after intensive chemoradiotherapy,
their chances of survival increased exponentially.
There are stem cells in the gut of the
laboratory mice that help preserve tissue after undergoing lethal doses of
chemoradiotherapy. Geng and colleagues found a way of getting the gut stem
cells to launch a massive healing campaign. Gene Print Predicts Who Will
Survive Chemotherapy
An 8-gene "print" or
"signature" can predict how long people remain cancer-free, without
any relapse after undergoing chemotherapy, researchers from Academia Sinica and
the National Taiwan University College of Medicine explained in the journal BMC
Medicine.
Prof Ker-Chau Li and team located genes that
are involved in cellular invasion - something several cancer cells do. They
gathered and examined data from the National Cancer
Institute's 60 human cancer cell line panel.
Prof. Li said "Our study found eight
genes which were involved in invasion, and the relative activation of these
genes correlated to chemotherapy outcome, including the receptor for growth
factor EGF. We also found that some invasion genes had unique patterns of
expression that reflect the differential cell responses to each of the
chemotherapy agents - five drugs (paclitaxel, docetaxel, erlotinib, everolimus
and dasatinib) had the greatest effect."
Cancer
Survivors
Ø
Cancer support groups
Ø
Cancer information workshops
Ø
Low-cost medical consultation
Ø
Increased government funding to seek
cures
AND
186,550
- The number of lives that could be saved each year if we ate a healthy diet
and exercised regularly
186,550
- The number of lives that could be saved each year with no tobacco
American Cancer Society